Oncotarget

Meta-Analysis:

Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis

Zheng-Xiao Zhao, Lin-Wei Lu, Jian Qiu, Qiu-Ping Li, Fei Xu, Bao-Jun Liu, Jing-Cheng Dong and Wei-Yi Gong _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:2728-2738. https://doi.org/10.18632/oncotarget.18964

Metrics: PDF 719 views  |   HTML 1396 views  |   ?  


Abstract

Zheng-Xiao Zhao1,2, Lin-Wei Lu1,2, Jian Qiu1,2, Qiu-Ping Li1,2, Fei Xu1,2, Bao-Jun Liu1,2, Jing-Cheng Dong1,2 and Wei-Yi Gong1,2

1Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China

2The Academy of Integrative Medicine of Fudan University, Shanghai 200032, P.R. China

Correspondence to:

Wei-Yi Gong, email: onlygwy119@163.com

Keywords: Glucose transporter-1, GLUT-1, cancer, prognosis, meta-analysis

Received: February 23, 2017     Accepted: June 18, 2017     Published: July 04, 2017

ABSTRACT

Objective: Glucose transporter-1 (GLUT-1) as the major glucose transporter present in human cells is found overexpressed in a proportion of human malignancies. This meta-analysis is attempted to assess the prognostic significance of GLUT-1 for survival in various cancers.

Materials and Methods: We conducted an electronic search using the databases PubMed, Embase and Web of Science, from inception to Oct 20th, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.

Results: Fourty-one studies with a total of 4794 patients were included. High GLUT-1 expression was significantly associated with poorer prognosis [overall survival: HR = 1.833 (95% CI: 1.597–2.069, P < 0.0001); disease-free survival: HR = 1.838 (95% CI: 1.264–2.673, P < 0.0001); progression-free survival: HR = 2.451 (95% CI: 1.668–3.233, P < 0.0001); disease specific survival: HR = 1.96 (95% CI: 1.05–2.871, P < 0.0001)].

Conclusions: High GLUT-1 expression may be an independent prognostic marker to predict poor survival in various types of cancers. Further clinical trials with high quality need to be conducted to confirm our conclusion.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18964